23ANDME HOLDING CO -CLASS A (ME)

US90138Q3065 - Common Stock

3.39  -0.25 (-6.87%)

Premarket: 3.39 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ME. ME was compared to 109 industry peers in the Health Care Providers & Services industry. While ME seems to be doing ok healthwise, there are quite some concerns on its profitability. ME has a expensive valuation and it also scores bad on growth.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

ME had negative earnings in the past year.
ME had a negative operating cash flow in the past year.
ME had negative earnings in each of the past 5 years.
ME had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -192.93%, ME is doing worse than 96.30% of the companies in the same industry.
ME has a Return On Equity of -603.67%. This is amonst the worse of the industry: ME underperforms 87.96% of its industry peers.
Industry RankSector Rank
ROA -192.93%
ROE -603.67%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 46.51%, ME is doing good in the industry, outperforming 74.07% of the companies in the same industry.
In the last couple of years the Gross Margin of ME has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for ME so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.93%
GM growth 5Y0.67%

More info and screens

5

2. Health

2.1 Basic Checks

ME does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for ME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -11.94, we must say that ME is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ME (-11.94) is worse than 92.59% of its industry peers.
ME has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.94
ROIC/WACCN/A
WACC9.43%

2.3 Liquidity

ME has a Current Ratio of 1.24. This is a normal value and indicates that ME is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.24, ME is not doing good in the industry: 62.96% of the companies in the same industry are doing better.
A Quick Ratio of 1.14 indicates that ME should not have too much problems paying its short term obligations.
ME has a Quick ratio of 1.14. This is in the lower half of the industry: ME underperforms 61.11% of its industry peers.
Industry RankSector Rank
Current Ratio 1.24
Quick Ratio 1.14

More info and screens

3

3. Growth

3.1 Past

ME shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -29.41%.
The Revenue for ME has decreased by -28.48% in the past year. This is quite bad
Measured over the past years, ME shows a very negative growth in Revenue. The Revenue has been decreasing by -13.01% on average per year.
EPS 1Y (TTM)-29.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1347.49%
Revenue 1Y (TTM)-28.48%
Revenue growth 3Y-3.43%
Revenue growth 5Y-13.01%
Sales Q2Q%-11.86%

3.2 Future

The Earnings Per Share is expected to grow by 25.35% on average over the next years. This is a very strong growth
Based on estimates for the next years, ME will show a quite strong growth in Revenue. The Revenue will grow by 19.08% on average per year.
EPS Next Y-329.17%
EPS Next 2Y-99.49%
EPS Next 3Y25.35%
EPS Next 5YN/A
Revenue Next Year22.37%
Revenue Next 2Y19.81%
Revenue Next 3Y5.77%
Revenue Next 5Y19.08%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ME is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

ME's earnings are expected to grow with 25.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-99.49%
EPS Next 3Y25.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ME!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

23ANDME HOLDING CO -CLASS A

NASDAQ:ME (1/14/2025, 8:00:01 PM)

Premarket: 3.39 0 (0%)

3.39

-0.25 (-6.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners30.13%
Inst Owner Change0%
Ins Owners2.42%
Ins Owner Change36.63%
Market Cap81.70M
Analysts84.44
Price Target40.8 (1103.54%)
Short Float %7.61%
Short Ratio3.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-15.14%
Min Revenue beat(2)-24.62%
Max Revenue beat(2)-5.66%
Revenue beat(4)1
Avg Revenue beat(4)-10.14%
Min Revenue beat(4)-24.62%
Max Revenue beat(4)9.3%
Revenue beat(8)3
Avg Revenue beat(8)-6.4%
Revenue beat(12)6
Avg Revenue beat(12)-3.1%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3205.79%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-9229.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)21.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.42
P/FCF N/A
P/OCF N/A
P/B 0.8
P/tB 1.57
EV/EBITDA N/A
EPS(TTM)-13.2
EYN/A
EPS(NY)-52.53
Fwd EYN/A
FCF(TTM)-5.4
FCFYN/A
OCF(TTM)-5.06
OCFYN/A
SpS8.02
BVpS4.23
TBVpS2.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -192.93%
ROE -603.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.51%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.93%
GM growth 5Y0.67%
F-Score4
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.79%
Cap/Sales 4.24%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.24
Quick Ratio 1.14
Altman-Z -11.94
F-Score4
WACC9.43%
ROIC/WACCN/A
Cap/Depr(3y)39.05%
Cap/Depr(5y)93.91%
Cap/Sales(3y)4.44%
Cap/Sales(5y)8.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1347.49%
EPS Next Y-329.17%
EPS Next 2Y-99.49%
EPS Next 3Y25.35%
EPS Next 5YN/A
Revenue 1Y (TTM)-28.48%
Revenue growth 3Y-3.43%
Revenue growth 5Y-13.01%
Sales Q2Q%-11.86%
Revenue Next Year22.37%
Revenue Next 2Y19.81%
Revenue Next 3Y5.77%
Revenue Next 5Y19.08%
EBIT growth 1Y22.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.03%
EBIT Next 3Y21.64%
EBIT Next 5YN/A
FCF growth 1Y39.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.69%
OCF growth 3YN/A
OCF growth 5YN/A